Abstract
During the last few years, adoptive cellular therapy (ACT) — the isolation of antigen-specific lymphocytes, their ex vivo expansion and activation, and subsequent autologous administration — has been tested for treatment of melanoma tumours. Initial ACT used melanoma -infiltrating lymphocytes (TIL) that often contain tumour reactive lymphocytes, of diverse, mostly unknown, specificities [1, 2]. Recently, the identification of melanoma antigens [3] and the development of techniques for selection and expansion of epitope specific T cells has opened the way to the use of tumour antigen specific T cells, and importantly to immune follow up of ACT [4-9]. Despite these advances, several issues remain to address to achieve the major aims of ACT, as the rapid production of clinical grade T cells capable of eliciting a significant destruction of tumour tissue.
Keywords: lymphocyte, TCR transgenic T cells, melanoma infiltrating lymphocytes, tumour antigen, Peripheral Blood Mononuclear Cell
Current Cancer Therapy Reviews
Title: Lymphocyte Biomarkers of Clinical Responses to Adoptive Immunotherapy of Malignant Melanoma
Volume: 4 Issue: 2
Author(s): Nathalie Labarriere, Brigitte Dreno and Francine Jotereau
Affiliation:
Keywords: lymphocyte, TCR transgenic T cells, melanoma infiltrating lymphocytes, tumour antigen, Peripheral Blood Mononuclear Cell
Abstract: During the last few years, adoptive cellular therapy (ACT) — the isolation of antigen-specific lymphocytes, their ex vivo expansion and activation, and subsequent autologous administration — has been tested for treatment of melanoma tumours. Initial ACT used melanoma -infiltrating lymphocytes (TIL) that often contain tumour reactive lymphocytes, of diverse, mostly unknown, specificities [1, 2]. Recently, the identification of melanoma antigens [3] and the development of techniques for selection and expansion of epitope specific T cells has opened the way to the use of tumour antigen specific T cells, and importantly to immune follow up of ACT [4-9]. Despite these advances, several issues remain to address to achieve the major aims of ACT, as the rapid production of clinical grade T cells capable of eliciting a significant destruction of tumour tissue.
Export Options
About this article
Cite this article as:
Labarriere Nathalie, Dreno Brigitte and Jotereau Francine, Lymphocyte Biomarkers of Clinical Responses to Adoptive Immunotherapy of Malignant Melanoma, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310142
DOI https://dx.doi.org/10.2174/157339408784310142 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gold and Silver Nanoparticles for Applications in Theranostics
Current Topics in Medicinal Chemistry Novel Molecular Targets in Cancer Chemotherapy Waiting for Discovery
Current Medicinal Chemistry - Anti-Cancer Agents Thioredoxin Reductase and its Inhibitors
Current Protein & Peptide Science Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets A Novel Nanoformulation of Ellagic Acid is Promising in Restoring Oxidative Homeostasis in Rat Brains with Alzheimer’s Disease
Current Drug Metabolism Metallopharmaceuticals in Therapy - A New Horizon for Scientific Research
Current Medicinal Chemistry The Quest for a Tumor Suppressor Gene Phenotype
Current Molecular Medicine Xiaoyao Pill Improves the Affective Dysregulation of Sleep-deprived Female Mice by Inhibiting Brain Injury and Regulating the Content of Monoamine Neurotransmitter
Current Pharmaceutical Biotechnology Multiple Forms of Proteasomes and their Role in Tumor Fate
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery IP6 & Inositol in Cancer Prevention and Therapy
Current Cancer Therapy Reviews Inhibition of Angiogenesis as a Treatment Strategy for Neuroblastoma
Current Cancer Therapy Reviews Ceramidases in Hematological Malignancies: Senseless or Neglected Target?
Anti-Cancer Agents in Medicinal Chemistry Chalcones in Cancer: Understanding their Role in Terms of QSAR
Current Medicinal Chemistry Antidiabetic Potential of Fabaceae Family: An Overview
Current Nutrition & Food Science Perspectives in Melanoma Treatment with Signal Transduction
Current Medicinal Chemistry - Anti-Cancer Agents Bone Seeking Radiopharmaceuticals for Palliation of Pain in Cancer Patients with Osseous Metastases
Anti-Cancer Agents in Medicinal Chemistry Editorial: New Insights into a Classical Pathway: Key Roles of the Mevalonate Cascade in Different Diseases (Part II)
Current Molecular Pharmacology A Glance Over the Cannabinoid Machinery to Design New Anti- Angiogenic Compounds
Mini-Reviews in Medicinal Chemistry Artificial Neural Networks in Cardiovascular Diseases and its Potential for Clinical Application in Molecular Imaging
Current Radiopharmaceuticals Absorption, Pharmacokinetics and Disposition of Biodegradable Nanoscale Preparations
Current Drug Metabolism